TIBER CREEK GROUP

Lobbying for ACADIA PHARMACEUTICALS, INC. · Biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $80,000.00 income · posted Apr 18, 2026

Lobbying activity 1

Health Issues

Issues related to rare disease treatments, including rare disease research incentives; Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to drug pricing reforms.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.